China's Epigenic Therapeutics has secured $20 million in Series Angel and Pre-A funding. Series Pre-A funding is jointly invested by Morningside Venture Capital, Kingray Capital, Trinity Innovation Fund and TigerYeah Capital. Angel investor FountainBridge Capital is also participating.

Proceeds of financing will be used to validate advances of the Company's proprietary epigenetic editing in non-human primates, expand expertise and capabilities, and sponsor early-stage clinical investigations.

Epigenetic modification is a natural and heritable gene regulation mechanism in the human body without altering the underlying DNA sequence. Leveraging company's proprietary and patented technology platform, scientists are able to harness endogenous epigenetic gene regulation pathway to precisely and efficiently deliver medicine to target cells and tissues, and achieve potent and durable therapeutic impact. Epigenic Therapeutics has gathered highly talented scientists and industry veterans to direct discovery and development.